The upcoming report from Illumina (ILMN) is expected to reveal quarterly earnings of $0.23 per share, indicating a decline of 28.1% compared to the year-ago period. Analysts forecast revenues of $1.1 billion, representing a decrease of 6.7% year over year.The current level reflects an upward revision of 54.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Ahead ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Illumina (ILMN) , which belongs to the Zacks Medical - Biomedical and Genetics industry.This genetic testing tools company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 750%.For the last reported quarter, Illumina came out with earnings of $0.09 per ...

Core Viewpoint - Illumina (ILMN) shares have increased by 5.5% recently, with a mean price target of $145.43 suggesting a potential upside of 27% from the current price of $114.49 [1] Price Targets and Analyst Consensus - The mean estimate of $145.43 is based on 21 short-term price targets, with a standard deviation of $36.38 indicating variability among analysts [1] - The lowest estimate of $100 suggests a 12.7% decline, while the highest estimate predicts a surge of 111.4% to $242 [1] - Analysts' price targets can often mislead investors, as they may set overly optimistic targets due to business incentives [3][4] Earnings Estimates and Potential Upside - Analysts show strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [5] - The Zacks Consensus Estimate for the current year has risen by 40.3% over the past month, with two estimates increasing and no negative revisions [5] - ILMN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [5]

SAN DIEGO, July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am Pacific Time. The event will feature presentations by members of Illumina's executive team and conclude with a Q&A session.Webcast DetailsThe webcast can be accessed through the Events & Presentations section of Illumina's Investor Relations website at investor.illumina.com. We recommend that participants pre-regi ...

Core Viewpoint - Illumina (ILMN) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Outlook - The Zacks Consensus Estimate for Illumina for the fiscal year ending December 2024 is projected at $0.98 per share, reflecting a 14% increase from the previous year's reported figure [5]. - Over the past three months, the Zacks Consensus Estimate for Illumina has risen by 7.7%, indicating a trend of increasing earnings estimates [5]. Impact of Earnings Estimates - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [3]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, which can lead to significant stock price movements based on their buying or selling activities [3]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [4]. - The upgrade of Illumina to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for price appreciation in the near term [7].

Illumina TodayILMNIllumina$116.56 +0.47 (+0.40%) 52-Week Range$89.00▼$195.64Price Target$158.57Add to WatchlistLife sciences company Illumina Inc. NASDAQ: ILMN stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of GRAIL, LLC NASDAQ: GRAL on June 24, 2024. Illumina had previously acquired the early detection cancer testing company for $8 billion in 2021.Get Illumina alerts:Illumina's GRAIL Acquisition Backfired, Resulting i ...

INDIA - 2023/12/16: In this photo illustration, the Illumina logo is seen displayed on a mobile ... [+] phone screen. (Photo Illustration by Idrees Abbas/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIllumina stock (NASDAQ: ILMN) saw a 6% rise on Wednesday, July 10, faring better than its peer — Mettler-Toledo stock – up 1%. The rise in ILMN stock can primarily be attributed to the company’s acquisition of Fluent Biosciences to expand its single-cell analysis and multiomic ...

SAN DIEGO, July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of market on Tuesday, August 6, 2024. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Cal ...

Loading...Loading...Wednesday, Illumina Inc ILMN acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration.Amid this M&A deal, 10x Genomics, Inc TXG shares are trading lower.William Blair writes that Fluent’s PIPseq single-cell technology does not require an instrument, and costs per cell is at least 50% less than 10x and is the cheapest on the market, citing a recent bioRxiv preprint.William Blair highlights that cost reduction has beco ...

Illumina, Inc. (ILMN) recently acquired Fluent BioSciences, a developer of innovative single-cell technology. This strategic acquisition marks a significant step in Illumina's expansion within the single-cell research domain, aligning with the company’s broader multiomics growth strategy.The acquisition was completed on Jul 9 and funded with cash on hand. However, other financial terms of the deal were not disclosed.Enhancing Single-Cell Research CapabilitiesFluent BioSciences has developed a highly differe ...